Loading...

Myomo, Inc.

MYONYSE
Healthcare
Medical - Devices
$1.85
$0.07(3.64%)

Myomo, Inc. (MYO) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for Myomo, Inc. (MYO), covering cash flow, earnings, and balance sheets.

Revenue Growth
69.17%
69.17%
Operating Income Growth
100.00%
100.00%
Net Income Growth
100.00%
100.00%
Operating Cash Flow Growth
46.70%
46.70%
Operating Margin
-15.11%
15.11%
Gross Margin
71.18%
71.18%
Net Profit Margin
-15.05%
15.05%
ROE
-35.57%
35.57%
ROIC
-20.00%
20.00%

Myomo, Inc. (MYO) Income Statement & Financial Overview

Explore comprehensive income reports for Myomo, Inc. MYO, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$9.83M$12.07M$9.21M$7.52M
Cost of Revenue$3.22M$3.45M$2.26M$2.20M
Gross Profit$6.61M$8.62M$6.95M$5.33M
Gross Profit Ratio$0.67$0.71$0.75$0.71
R&D Expenses$1.79M$1.56M$1.25M$1.007M
SG&A Expenses$8.34M$7.30M$6.65M$5.43M
Operating Expenses$10.13M$8.86M$7.90M$6.44M
Total Costs & Expenses$13.35M$12.31M$10.17M$8.64M
Interest Income$0.00$70031.00$76020.00$107242.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$0.00$466034.00$0.00$101377.00
EBITDA-$3.52M$290751.00-$957553.00-$1.01M
EBITDA Ratio-$0.36$0.02-$0.10-$0.13
Operating Income-$3.52M-$245314.00-$957553.00-$1.12M
Operating Income Ratio-$0.36-$0.02-$0.10-$0.15
Other Income/Expenses (Net)$191991.00$70031.00$76020.00$107242.00
Income Before Tax-$3.33M-$175283.00-$881533.00-$1.008M
Income Before Tax Ratio-$0.34-$0.01-$0.10-$0.13
Income Tax Expense$136795.00$84798.00$84876.00$113785.00
Net Income-$3.47M-$260081.00-$966409.00-$1.12M
Net Income Ratio-$0.35-$0.02-$0.10-$0.15
EPS-$0.08-$0.007-$0.03-$0.03
Diluted EPS-$0.08-$0.007-$0.03-$0.03
Weighted Avg Shares Outstanding$41.45M$38.91M$37.95M$37.37M
Weighted Avg Shares Outstanding (Diluted)$41.45M$38.91M$37.95M$37.37M

The company's financials show resilient growth, with revenue advancing from $7.52M in Q2 2024 to $9.83M in Q1 2025. Gross profit remained healthy with margins at 67% in Q1 2025 compared to 71% in Q2 2024. Operating income hit -$3.52M last quarter, sustaining a consistent -36% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$3.52M. Net income dropped to -$3.47M, while earnings per share reached -$0.08. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;